Condition: HPV-positive Oropharyngeal Squamous Cell Carcinoma · Sponsor: Icahn School of Medicine at Mount Sinai
The purpose of this study is to determine whether treatment of HPV-related oropharyngeal squamous cell carcinoma in patients with undetectable postoperative HPV circulating tumor DNA (cfHPVDNA) with transoral robotic surgery (TORS) alone can result in cancer control and survival comparable to those previously reported with standard therapy. The protocol includes patients with only with low or intermediate pathologic risk factors following surgery with detectable pre-surgery cfHPVDNA and undetectable post-surgery cfHPVDNA. The hope is that with this approach, the long-term complications from chemotherapy and radiation can be reduced.
This description comes directly from the study's public registry record.
Mabel Korley · (212) 731-3297 · mabel.korley@mountsinai.org
Chanel Rojas · (347) 962-6630 · chanel.rojas@mountsinai.org
Always discuss trial participation with your own doctor first.
| Valley - Mount Sinai Comprehensive Cancer Care | Paramus, New Jersey, United States | Recruiting |
| Mount Sinai Health System | New York, New York, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05419089